Berwyn-based Annovis Bio, a clinical-stage drug platform company, recently exceeded full enrollment for its lead compound buntanetap phase II/III study.
The compound is used to treat patients with mild to moderate Alzheimer’s (AD).
The randomized, double-blind, placebo-controlled study began in March. More than 700 patients were screened, and 353 were enrolled at 54 sites nationwide.
“We are very pleased to share the news of the successful completion of enrollment for our phase II/III study of buntanetap in Alzheimer’s Disease,” Dr. Maria Maccecchini, Annovis founder, president and CEO, said. “The number of enrolled patients exceeded our initial projections, revealing the Alzheimer’s community’s strong endorsement of our mission to develop a treatment targeting multiple neurotoxic proteins. This not only proves their support but also underscores their willingness to contribute to advancing this important cause.”
The company is investigating the efficacy, safety, and tolerability of buntanetap. For 12 weeks, patients receive one of three doses of buntanetap in addition to any medications they had been previously taking.
Buntanetap reduces levels of multiple neurotoxic proteins to improve synaptic transmission and axonal transport, and reduce inflammation, a cause of cell death.
In October, the company announced a positive efficacy interim analysis.
Annovis expects data from the study to be available by April.